Core Viewpoint - Revolution Medicines, Inc. (RVMD) has shown a 1% increase in share price over the past four weeks, closing at $42.19, with analysts suggesting a potential upside of 74.1% based on a mean price target of $73.43 [1] Price Targets - The average of 14 short-term price targets ranges from a low of $62 to a high of $87, with a standard deviation of $7.41, indicating a potential increase of 47% to 106.2% from the current price level [2] - A low standard deviation suggests a strong agreement among analysts regarding the price targets, which can be a good starting point for further research [7] Analyst Sentiment - There is a growing optimism among analysts regarding RVMD's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [9] - The Zacks Consensus Estimate for the current year has increased by 1% over the past month, with no negative revisions, indicating a favorable outlook [10] Zacks Rank - RVMD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside in the near term [11] Caution on Price Targets - While price targets can provide insights, relying solely on them for investment decisions may lead to disappointing returns, and they should be approached with skepticism [8][12]

Core Insights - Revolution Medicines, Inc. is a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers [3] - The company will participate in the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025, with CEO Mark A. Goldsmith as a speaker [1] Company Overview - Revolution Medicines is developing RAS(ON) inhibitors aimed at suppressing various oncogenic variants of RAS proteins [3] - The R&D pipeline includes daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805), which are currently in clinical development [3] - Additional pipeline opportunities focus on RAS(ON) mutant-selective inhibitors such as RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C) [3]

Revolution Medicines, Inc. (RVMD) has been on a downward spiral lately with significant selling pressure. After declining 7% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whet ...

REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. PT. To access the live webcast of the presentation, pleas ...

REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the closing of its underwritten public offering of 16,576,088 shares of its common stock at a public offering price of $46.00 per share, before underwriting discounts and commissions, and, in lieu of shares of common stock, to certain investors, pre-funded warrants to purchase 2,173,917 share ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.I last covered Revolution Medicines (NASDAQ: RVMD ) for Seeking Alpha back in April, assigning the biotech drug discovery company's stock a "Hold" rating. Shares have risen ...

REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the pricing of 14,130,436 shares of its common stock at a public offering price of $46.00 per share, before underwriting discounts and commissions, and, in lieu of shares of common stock, to certain investors, pre-funded warrants to purchase 2,173,917 shares of common stock at a public offeri ...

REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has commenced an underwritten public offering to sell up to $600.0 million of shares of its common stock. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines intends to grant the underwriters a 30-day option to purchase up to ...

Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute 302 clinical trial Phase 1/1b proof-of-concept for RMC-6236 monotherapy in previously treated non-small cell lung cancer supports Phase 3 RASolve 301 clinical trial expected to be initiated in Q1 2025 Favorable initial safety profile for combination of pembrolizumab with either RMC-6236 or RMC-6291 supports continued evaluation in non-small cell lung cancer Initia ...

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide clinical updates from its RAS(ON) inhibitor portfolio. The webcast will take place at 8:00 a.m. Eastern Time on Monday, December 2, 2024. To access the webcast, click here. An archived replay will be available on the “Events & Presentations” p ...